Last reviewed · How we verify
NCT06216340
Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes
Phase 4 trial testing Henagliflozin in Obese in 300 participants. Not yet recruiting.
1 October 2026
Quick facts
| Lead sponsor | The First People's Hospital of Changzhou |
|---|---|
| Phase | Phase 4 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 300 |
| Start date | 15 February 2024 |
| Primary completion | 1 October 2026 |
| Estimated completion | 1 October 2026 |
Drugs / interventions tested
- Henagliflozin — full drug profile →
- Placebo
Conditions studied
- Obese — all drugs for Obese →
- Weight Loss — all drugs for Weight Loss →
- Pre-diabetes — all drugs for Pre-diabetes →
Sponsor
The First People's Hospital of Changzhou
Who can join
Adults 18 to 65, any sex, with Obese or Weight Loss. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial is conducted in China. The purpose of the 24-week trial is to investigate the efficacy of henagliflozin to induce body weight loss and the purpose of the extension is to evaluate the hypoglycemic effect of henagliflozin in obese subjects without diabetes. Trial has the following two periods: 1) A 12-week randomized, double-blind, placebo-controlled, multi-center trial for evaluating the efficacy of henagliflozin to induce body weight loss; 2) A 12-week multicenter randomized controlled open-label trial for evaluating the hypoglycemic effect of henagliflozin followed by a 24-week extension period.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy.
Nicze M, Dec A, Borówka M, Krzyżak D, et al · · 2024 · cited 9× · PMID 39125772 · DOI 10.3390/ijms25158202
Verify or expand the search:
- PubMed search for NCT06216340
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Henagliflozin
Trials testing the same drug.
- NCT06085703 — Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel C · NA · completed
- NCT06218342 — Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease · Phase 4 · unknown
- NCT06031389 — Henagliflozin Delays the Progress of Diabetic Nephropathy Via Regulates Gut-Renal Axis · NA · unknown
- NCT06059287 — The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics · NA · unknown
- NCT06187727 — Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction · Phase 4 · completed
Other recruiting trials for Obese
Currently open trials in the same condition.
- NCT07411560 — A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in Peopl · Phase 1 · recruiting
- NCT06719466 — Diet Intervention on Obesity Related Complication · NA · active not recruiting
- NCT06590584 — Validity and Reliability of the 6-minute Pegboard Ring Test in Obese Individuals · recruiting
- NCT06562660 — The Effect of Mask Combined With High Flow Oxygen on Preoxygenation During Induction of General Anesthesia in Obese Pati · NA · recruiting
- NCT05819853 — Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome · Phase 3 · recruiting
Other The First People's Hospital of Changzhou trials
Trials by the same sponsor.
- NCT06867991 — Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis · Phase 3 · recruiting
- NCT06950242 — Clinical Trial of Safety and Efficacy of Intracranial Laser Balloon Dilation Catheter in Patients With Symptomatic Intra · NA · enrolling by invitation
- NCT06618222 — Wingspan Stent System for Intracranial Artery Stenosis · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06216340 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First People's Hospital of Changzhou
- Last refreshed: 22 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06216340.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing